|Last Price$21.23||Day Change (%)-0.28%|
|Open Price$21.20||Day Change ($)-0.06|
|Day Range21.10–21.34||52-Week Range17.71–21.72|
As of Fri 9/23/2016 5:28:00 PM | USD
European Commission Approves Ipsen’s Cabometyx™ (Cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma (RCC) in Adults Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy
European Commission Approves CABOMETYX™ (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy
Pfizer Receives Positive CHMP Opinion For IBRANCE® (palbociclib) In Combination With Endocrine Therapy For The Treatment Of HR+/HER2- Metastatic Breast Cancer In Europe
World’s Leading Packet Flow Switch Adds High-Density 40G for Large-Scale Enterprise and Service Provider Networks
FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer
Phase III Study Showed Genentech’s Cancer Immunotherapy TECENTRIQ™ (Atezolizumab) Helped People with a Specific Type of Lung Cancer Live Significantly Longer Compared to Chemotherapy
A curious move, at a curious time, for purportedly, a curious reason, that is also a slap in the face to CPAs with the PFS credential.
This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...
Before investing you should carefully consider the Fund’s investment objectives, risks, charges and expenses. This and other information is in the prospectus. Please read the prospectus carefully before you invest. Foreside Fund Services, LLC, Distributor. An investment in the Funds is subject to ...
To the extent that this content includes references to securities, those references do not constitute an offer or solicitation to buy, sell or hold such security. AdvisorShares is a sponsor of actively managed exchange-traded funds (ETFs) and holds positions in all of its ETFs. This document should ...